Percentage of free to total PSA as a biomarker of survival in metastatic castration‐resistant prostate cancer

Documenti analoghi

• What are we missing? Identifying clinically significant prostate cancer among patients with low PSA : the utility of the free‐to‐total PSA ratio
  di: Daniel Crisafi, et al.
  Pubblicazione: (2025)
• Utility of PSA free‐to‐total ratio for clinically significant prostate cancer in men with a PSA level of <4 ng/mL
  di: Samuel Sii, et al.
  Pubblicazione: (2024)
• Urologist underutilisation of androgen receptor pathway inhibitors for metastatic hormone‐sensitive prostate cancer
  di: Daniel Crisafi, et al.
  Pubblicazione: (2024)
• The impact of progression‐directed therapy on survival in metastatic castration‐refractory prostate cancer: MEDCARE phase 3 trial
  di: Kato Rans, et al.
  Pubblicazione: (2024)
• Primary retroperitoneal lymph node dissection in stage II testicular seminoma: a systematic review
  di: Jianliang Liu, et al.
  Pubblicazione: (2024)